Please use this identifier to cite or link to this item:
https://open.uns.ac.rs/handle/123456789/1084
Title: | Anti-annexin A5 antibodies and 25-hydroxy-cholecalciferol in female patients with primary antiphospholipid syndrome | Authors: | Mirjana Bećarević Marija Sarić Ljudmila Stojanović Duško Mirković Violeta Dopsaj Svetlana Ignjatović |
Keywords: | 25-hydroxy-cholecalciferol;Anti-annexin A5 antibodies;Antiphospholipid antibodies;Antiphospholipid syndrome;Vitamin D3 | Issue Date: | 1-Dec-2018 | Project: | Biomarkeri oštećenja i disfunkcije organa (RS-175036) Ministry of Science, Education and Technological Development of the Republic of Serbia | Journal: | Clinical Rheumatology | Abstract: | © 2018, International League of Associations for Rheumatology (ILAR). Vascular antiphospholipid syndrome (VAPS) and obstetric (OAPS) are different entities because some patients only develop thrombosis (without recurrent pregnancy losses) and vice versa. Only two articles have reported that low 25-hydroxy-cholecalciferol (vitamin D3, VD3) levels were not correlated with the presence of conventional antiphospholipid antibodies (aPL Abs: anticardiolipin (aCL), anti-beta2glycoprotein I (aβ2gpI), and lupus anticoagulant (LA)), but no article analyzed the association of VD3 and anti-annexin A5 (aanxA5) Abs. The aim of our study was to investigate the association between VD3, multiple positivity of conventional aPL and aanxA5 Abs levels only in female OAPS vs. VAPS. Our study included 62 consecutive female PAPS patients. Concentrations of Abs were measured by ELISA, while VD3 levels were determined by immunochemiluminescence. Only 10/62 (16.13%) had sufficient (≥ 30 ng/ml) VD3 levels, while 48/62 (77.42%) and 4/62 (6.45%) had insufficiency and VD3 deficiency, respectively. Statistically significant VD3 deficiency was noticed in VAPS (vs. OAPS, P = 0.013). A negative correlation between VD3 levels and the age of patients was noticed (r = − 0.493, P = 0.032) only in VAPS subgroup. Multiple positivity of aPL and aanxA5 Abs was not associated with VD3 deficiency. Newly emerging aPL Abs, such as aanxA5 Abs, or their combinations with classical aPL Abs are not associated with VD3 deficiency in neither OAPS nor VAPS patients. Due to its immunomodulatory roles in B-Ly homeostasis, supplementation with VD3 should be considered in APS, at least in subgroup with severe form of the disease, i.e., VAPS. | URI: | https://open.uns.ac.rs/handle/123456789/1084 | ISSN: | 7703198 | DOI: | 10.1007/s10067-018-4170-7 |
Appears in Collections: | MDF Publikacije/Publications |
Show full item record
SCOPUSTM
Citations
2
checked on May 3, 2024
Page view(s)
42
Last Week
5
5
Last month
2
2
checked on May 3, 2024
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.